PRKN and Parkinson disease: To verify the applicability of the proposed method to drug screening of PD, we screened 320 pharmacologically active inhibitor compounds for their ability to improve mitochondrial clearance and cell viability in PARK2 and PARK6 iPSC-derived neurons.